DOCSLIB.ORG

Monoclonal Antibodies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Monoclonal Antibodies Monoclonal Antibodies A Review of Pertinent Drug Information for SARS-CoV-2 Jessica Ortwine, PharmD, BCIDP Clinical Pharmacy Specialist, Parkland Health & Hospital System [email protected] @jkortwine Data as of February 25, 2021 Adaptive Immunity • Active immunity: seroconversion occurs within 1-3 weeks of COVID-19 symptom onset • Passive immunity: direct administration of monoclonal antibodies (mAb) or convalescent plasma • Benefit of mAb: target specific viral epitopes and domains, mass produced, administered in a specified quantity, no reliance on donors Zhao J, et al. Clin Infect Dis. 2020;71:2027-34. https://doi.org/10.1093/cid/ciaa344 Mechanism of Action • Monoclonal antibodies prevent and possibly treat COVID-19 via multiple effector functions • Antibody-mediated neutralization of pathogen • Antibody-dependent cellular cytotoxicity • Antibody-dependent cellular phagocytosis Lu LL, et al. Nat Rev Immunol. 2018;18:46-61. https://doi.org/10.1038/nri.2017.106 Mechanism of Action • Spike (S) protein essential for: • Viral attachment to host receptor (S1) • Virus-cell fusion (S2) • Monoclonal antibodies (mAbs) bind to receptor binding domain (RBD) of S protein • Block viral entry into host cells Jiang S, et al. Trends Immunol. 2020;41:355-9. https://doi.org/10.1016/j.it.2020.03.007 Eli Lilly – Bamlanivimab Alternate Names: LY3819253 LY-CoV555 Bamlanivimab – In vitro Activity • Greater neutralization potency than other RBD-binding, ACE2- Neutralization Potency blocking antibody finalists, despite similar binding affinities • Ability to bind to RBD in both “up” and “down” conformations may account for increased neutralization activity Jones BE, et al. bioRxiv [Preprint]. 2020. https://doi.org/10.1101/2020.09.30.318972 In vivo Animal Data Rhesus Macaque Prophylaxis Methods Antibody administered intravenously 1 day prior to viral challenge Viral Inoculum 1.1 x 105 PFU 1 mg/kg (N=4) 2.5 mg/kg (N=4) Antibody Doses 15 mg/kg (N=3) 50 mg/kg (N=3) Control (N=4) Lower respiratory tract (LRT): Nasal swab, throat swab Sample Types Upper respiratory tract (URT): BAL, lung tissue Outcomes Change in viral load (gRNA and sgRNA) Jones BE, et al. bioRxiv [Preprint]. 2020. https://doi.org/10.1101/2020.09.30.318972 In vivo Animal Data Rhesus Macaque Key Findings • Reduced viral concentrations and replication on day 1 in all BAL and most LRT samples • Viral replication undetectable in all locations by day 3 at most doses Jones BE, et al. bioRxiv [Preprint]. 2020. https://doi.org/10.1101/2020.09.30.318972 Eli Lilly – Etesevimab Alternate Names: JS016 LY3832479 LY-CoV016 Etesevimab – In vitro Activity • Two potential monoclonal antibodies initially identified from convalescing patient • Similar ability to block binding of SARS-CoV-2 RBD to ACE2 receptor • Bind to overlapping epitopes • Lower 50% neutralization dose against infected cells for CB6 Shi R, et al. Nature. 2020;584:120-4. https://doi.org/10.1038/s41586-020-2381-y In vivo Animal Data Rhesus Macaque Prophylaxis Treatment Antibody administered 1 day prior Antibody administered on day 1 and day Methods to viral challenge 3 post-viral challenge 5 Viral Inoculum 1.0 x 10 TCID50 50 mg/kg (N=3/group) Antibody Dose Placebo (N=3) Sample Type Throat swabs Change in viral load (RNA) Outcomes Pathological lung damage Shi R, et al. Nature. 2020;584:120-4. https://doi.org/10.1038/s41586-020-2381-y In vivo Animal Data Rhesus Macaque Key Findings • Low levels of virus detectable among animals receiving prophylactic doses • Treatment doses resulted in reduced viral loads by day 2 compared to placebo • Reduced infection-related lung damage in both prophylaxed and treated animals Shi R, et al. Nature. 2020;584:120-4. https://doi.org/10.1038/s41586-020-2381-y Clinical Trials NCT Number Patient Population Treatment Groups Status LY-CoV555 NCT04427501 Recruiting – some results Treatment of outpatients with mild to moderate COVID-19 illness LY-CoV555 + LY-CoV016 BLAZE-1 available Placebo LY-CoV555 NCT04497987 Prevention (and treatment) of COVID-19 illness in skilled nursing and Recruiting – press release LY-CoV555 + LY-CoV016 (treatment arm only) BLAZE-2 assisted living facility residents and staff data available Placebo LY-CoV555 NCT04634409 LY-CoV555 + LY-CoV016 Recruiting – press release Treatment of outpatients with mild to moderate COVID-19 illness BLAZE-4 LY-CoV555 + VIR-7831 data available Placebo NCT04701658 Treatment of outpatients with mild-to-moderate COVID-19 at high risk LY-CoV555 Not yet recruiting BLAZE-5 for progressing to severe illness Standard of care NCT04518410 LY-CoV555 Treatment of outpatients with mild to moderate COVID-19 illness Recruiting ACTIV-2 Placebo NCT04501978 LY-CoV555 Treatment of hospitalized patients with COVID-19 illness Halted – results available ACTIV-3 Placebo Source: https://clinicaltrials.gov Ambulatory Treatment BLAZE-1 Study Design Treatment Groups Outcomes • Phase 2, double-blind RCT • Part A: LY-CoV555 • Primary: • Non-hospitalized adults monotherapy • Change from baseline viral • 7000 mg IV x 1 load at day 11 (± 4 days) • ≥ 1 mild/moderate COVID- • 2800 mg IV x 1 from positive results 19 symptom • 700 mg IV x 1 • Secondary: • 1st positive SARS-CoV-2 • Placebo • Safety test ≤ 72 hours from start • Part B & C: LY-CoV555 + • Symptom burden of infusion LY-CoV016 combination • COVID-19 related hospitalization, ED visit, or • High risk for complications • 2800 mg/2800 mg IV x 1 (Part C only) death at day 29 • Placebo • Viral clearance Chen P, et al. N Engl J Med. 2021;384(3):229-37. https://doi.org/10.1056/NEJMoa2029849 Gottlieb RL, et al. JAMA. 2021. [Epub ahead of print]. https://doi.org/10.1001/jama.2021.0202 Ambulatory Treatment LY- CoV555 Monotherapy Characteristic Ly-CoV555 (N=309) Placebo (N=143) Ly-CoV555 dosing: Age (years), median (range) 45 (18-86) 46 (18-77) ≥ 65, n (%) 33 (10.7) 20 (14.0) • 700 mg (N=101) Body-mass index (kg/m2), median 29.4 29.1 • 2800 mg (N=107) ≥ 30 to < 40, n/total (%) 112/304 (36.8) 56/139 (40.3) • 7000 mg (N=101) ≥ 40, no/total (%) 24/304 (7.9) 9/139 (6.5) Risk factors for severe COVID-19, n(%) 215 (69.6) 95 (66.4) Disease status, n(%) Risk factors for severe disease: Mild 232 (75.1) 113 (79.0) • Age ≥ 65 years Moderate 77 (24.9) 30 (21.0) • BMI ≥ 35 kg/m2 Days since symptom onset, median 4.0 4.0 • Prespecified coexisting illness Viral load (cycle threshold), mean 23.9 23.8 Chen P, et al. N Engl J Med. 2021;384(3):229-37. https://doi.org/10.1056/NEJMoa2029849 Ambulatory Treatment LY- CoV555 Monotherapy Primary Outcome: Mean change from baseline in viral load at day 11 Treatment Group Viral Load Change, mean Difference (95% CI) Placebo -3.47 LY-CoV555, 700 mg -3.67 -0.20 (-0.66 to 0.25) LY-CoV555, 2800 mg -4.00 -0.53 (-0.98 to -0.08) LY-CoV555, 7000 mg -3.38 0.09 (-0.37 to 0.55) Pooled LY-CoV555 doses -3.70 -0.22 (-0.60 to 0.15) Chen P, et al. N Engl J Med. 2021;384(3):229-37. https://doi.org/10.1056/NEJMoa2029849 Ambulatory Treatment LY- CoV555 Monotherapy Secondary Outcome: Mean change from baseline in viral load at days 3 and 7 Day 3 Day 5 Treatment Group Viral Load Change, Difference Viral Load Change, Difference mean (95% CI) mean (95% CI) Placebo -0.85 -2.56 LY-CoV555, 700 mg -1.27 -0.42 (-0.89 to 0.06) -2.82 -0.25 (-0.73 to 0.23) LY-CoV555, 2800 mg -1.50 -0.64 (-1.11 to -0.17) -3.01 -0.45 (-0.92 to 0.03) LY-CoV555, 7000 mg -1.27 -0.42 (-0.90 to 0.06) -2.85 -0.28 (-0.77 to 0.20) Pooled LY-CoV555 doses -1.35 -0.49 (-0.87 to -0.11) -2.90 -0.33 (-0.72 to 0.06) Chen P, et al. N Engl J Med. 2021;384(3):229-37. https://doi.org/10.1056/NEJMoa2029849 Ambulatory Treatment LY- CoV555 Monotherapy Secondary Outcomes: Hospitalizations, ED visits and Death • No deaths in any treatment group Treatment Group Hospitalization/ER Visits at Day 29* • Nearly all events were hospitalizations Placebo 9/143 (6.3) • 2 ED visits in placebo group • Post hoc analysis of high-risk patients LY-CoV555, 700 mg 1/101 (1.0) • LY-CoV555: 4/96 (4%) hospitalizations LY-CoV555, 2800 mg 2/107 (1.9) • Placebo: 7/48 (15%) hospitalizations LY-CoV555, 7000 mg 2/101 (2.0) Pooled LY-CoV555 doses 5/309 (1.6) *Placebo: 7 hospitalizations, 2 ER visits; LY-CoV555 all doses: 5 hospitalizations Chen P, et al. N Engl J Med. 2021;384(3):229-37. https://doi.org/10.1056/NEJMoa2029849 Emergency Use Authorization for bamlanivimab 700mg IV. Center for Drug Evaluation and Research (CDER) Review. Available at: https://www.fda.gov/media/144118/download Ambulatory Treatment LY- CoV555 Monotherapy Secondary Outcomes: Symptom Score • Median time to symptom improvement • Pooled treatment: 6 days • Placebo: 8 days Chen P, et al. N Engl J Med. 2021;384(3):229-37. https://doi.org/10.1056/NEJMoa2029849 US FDA: Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Bamlanivimab. Available at: https://www.fda.gov/media/143603/download Ambulatory Treatment LY- CoV555 Monotherapy Secondary Outcomes: Safety LY-CoV555 (N=309) Placebo 700 mg 2800 mg 7000 mg Pooled Doses (N=143) (N=101) (N=107) (N=101) (N=309) Serious adverse events, n(%) 0 0 0 0 1 (0.7) Adverse events Any 24 (23.8) 23 (21.5) 22 (21.8) 69 (22.3) 35 (24.5) Mild 16 (15.8) 18 (16.8) 10 (9.9) 44 (14.2) 18 (12.6) Moderate 7 (6.9) 3 (2.8) 8 (7.9) 18 (5.8) 16 (11.2) Severe 0 2 (1.9) 3 (3.0) 5 (1.6) 1 (0.7) Infusion-related reactions -- -- -- 7 (2.3) 2 (1.4) Chen P, et al.
Load more

Recommended publications
  • Emergency Use Authorization (EUA) for Sotrovimab 500 Mg Center for Drug Evaluation and Research (CDER) Review
    Emergency Use Authorization (EUA) for Sotrovimab 500 mg Center for Drug Evaluation and Research (CDER) Review Identifying Information Application Type EUA (EUA or Pre-EUA) If EUA, designate whether pre-event or intra-event EUA request. EUA Application EUA 000100 Number(s) Sponsor (entity EUA Sponsor requesting EUA or GlaxoSmithKline Research & Development Limited pre-EUA 980 Great West Road consideration), point Brentford Middlesex, TW8 9GS of contact, address, UK phone number, fax number, email GSK US Point of Contact address Debra H. Lake, M.S. Sr. Director Global Regulatory Affairs GlaxoSmithKline 5 Moore Drive PO Box 13398 Research Triangle Park, NC 27709-3398 (b) (6) Email: Phone Manufacturer, if GlaxoSmithKline, Parma. different from Sponsor Submission Date(s) Part 1: March 24, 2021 Part 2: March 29, 2021 Receipt Date(s) Part 1: March 24, 2021 Part 2: March 29, 2021 OND Division / Office Division of Antivirals /Office of Infectious Disease 1 Reference ID: 4802027 Product in the No Strategic National Stockpile (SNS) Distributor, if other (b) (4) than Sponsor I. EUA Determination/Declaration On February 4, 2020, the Secretary of Health and Human Services determined pursuant to section 564 of the Federal Food, Drug and Cosmetic (FD&C) Act that there is a public health emergency that has a significant potential to affect national security or the health and security of United States (US) citizens living abroad and that involves a novel (new) coronavirus (nCoV) first detected in Wuhan City, Hubei Province, China in 2019 (2019-nCoV). The virus is now named SARS-CoV-2, which causes the illness COVID-19.
    [Show full text]
  • Progress in the Development of Potential Therapeutics and Vaccines Against COVID-19 Pandemic
    Acta Scientific Pharmaceutical Sciences (ISSN: 2581-5423) Volume 5 Issue 7 July 2021 Review Article Progress in the Development of Potential Therapeutics and Vaccines against COVID-19 Pandemic Abhishek Kumar Yadav, Shubham Kumar and Vikramdeep Monga* Received: May 02, 2021 Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, Published: June 09, 2021 India © All rights are reserved by Vikramdeep *Corresponding Author: Vikramdeep Monga, Department of Pharmaceutical Monga., et al. Chemistry, ISF College of Pharmacy, Moga, Punjab, India. Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19 or coronavirus disease 2019 and the same has been declared as a global pandemic by WHO which marked the third introduction of a virulent coronavirus into human society. This a threat to human life worldwide. Considerable efforts have been made for developing effective and safe drugs and vaccines against is a highly pathogenic human coronavirus in which pneumonia of unknown origin was identified in China in December 2019 and is SARS-CoV-2. The current situation and progress in the development of various therapeutic candidates including vaccines in preclini- cal and clinical studies have been described in the manuscript. Until now, many people have been infected with this lethal virus, and a lot of people have died from this COVID-19. This viral disease spreads by coming in contact with an infected person. Understand- ing of SARS-CoV-2 is growing in relation to its epidemiology, virology, and clinical management strategies. Till date, very few drugs or vaccines have been developed or approved for the treatment of this deadly disease of COVID-19 and many candidates are under the clinical development pipeline.
    [Show full text]
  • Updates on COVID-19 Monoclonal Antibody Treatment In
    Updates on COVID-19 Monoclonal Antibody (mAb) Treatment in the Outpatient Setting Overview • All providers should know how and when to refer patients for monoclonal antibody (mAB) treatment. • mAb treatment, when given early after symptom onset, can decrease the risk of hospitalization and death due to COVID-19 by as much as 70% to 85%. • Eligibility criteria for mAb treatment have been expanded to include additional medical conditions and factors that may place patients at high risk for progression to severe COVID-19. • Continue to refer eligible symptomatic patients for mAb treatment, regardless of vaccination status. • Sotrovimab is a new mAb product that has been granted emergency use authorization (EUA) by the Food and Drug Administration (FDA). • The EUA for REGEN-COV (casirivimab + imdevimab) has been updated to reduce the dose and allow for subcutaneous administration. • The EUA for REGEN-COV has also been expanded to include use as post-exposure prophylaxis for people exposed to someone with COVID-19 and at high risk for severe illness. • Health care providers should use only REGEN-COV or sotrovimab for the treatment of COVID-19 until further notice due to increasing prevalence of SARS-CoV-2 variants resistant to bamlanivimab and etesevimab. August 20, 2021 Dear Colleague, This letter summarizes important updates on monoclonal antibody (mAb) emergency use authorizations (EUAs) and treatment guidance. mAbs are the only authorized treatment option for patients with mild to moderate COVID-19 who are at high risk of developing severe illness. It is also the only option for post-exposure prophylaxis (PEP). As cases of COVID-19 continue to rise in New York City (NYC) due to more contagious and dangerous variants, it is critical that providers assist eligible patients to access this life-saving treatment by increasing patient awareness, encouraging prompt diagnostic testing following a COVID-19 exposure or symptom onset, and offering or referring patients for treatment.
    [Show full text]
  • Policy Brief 002 Update 07.2021
    Content ................................................................................................................................................................ 3 1 Background: policy question and methods ................................................................................................. 7 1.1 Policy Question ............................................................................................................................................. 7 1.2 Methodology ................................................................................................................................................. 7 1.3 Selection of Products for “Vignettes” ........................................................................................................ 10 2 Results: Vaccines ......................................................................................................................................... 13 2.1 Moderna Therapeutics—US National Institute of Allergy ..................................................................... 25 2.2 University of Oxford/ Astra Zeneca .......................................................................................................... 26 2.3 BioNTech/Fosun Pharma/Pfizer .............................................................................................................. 27 2.4 Janssen Pharmaceutical/ Johnson & Johnson .......................................................................................... 29 2.5 Novavax ......................................................................................................................................................
    [Show full text]
  • Regdanvimab for the Treatment of COVID-19
    25 March 2021 EMA/192245/2021 Committee for Medicinal Products for Human Use (CHMP) Assessment report Procedure under Article 5(3) of Regulation (EC) No 726/2004 Celltrion use of regdanvimab for the treatment of COVID-19 INN/active substance: regdanvimab Procedure number: EMEA/H/A-5(3)/1505 Note: Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. Table of contents Table of contents ......................................................................................... 2 1. Information on the procedure ................................................................. 3 2. Scientific discussion ................................................................................ 3 2.1. Introduction......................................................................................................... 3 2.2. Clinical aspects .................................................................................................... 4 2.2.1. Clinical pharmacology ........................................................................................ 6 2.2.2. Data on efficacy ...............................................................................................
    [Show full text]
  • FCDPH- Health Update- Monoclonal Antibody Treatments for COVID-19
    County of Fresno DEPARTMENT OF PUBLIC HEALTH Health Update August 16, 2021 Monoclonal Antibody Treatments for COVID-19 On January 4, 2021, The Fresno County Department of Public Health (FCDPH) recommended monoclonal antibodies as COVID-19 treatment options available to healthcare providers. The U.S. Food and Drug Administration (FDA) has updated the Fact Sheet on the availability of REGEN-COV (casirivimab and imdevimab, administered together) monoclonal antibody therapy for post-exposure prophylaxis (prevention) for COVID-19. Currently, casirivimab/imdevimab (REGEN-COV or Regeneron) and Sotrovimab have FDA EUA authorization for use in mild to moderate COVID-19. Sites offering MAB treatments are listed on page 5 of this Health Update. Monoclonal antibodies are an important tool in keeping patients from deteriorating and to assist the health care system from becoming overwhelmed. Preliminary data suggests a 2/3 to 3/4 reduction in emergency room visits and hospitalizations among high-risk COVID-19 positive patients who received monoclonal antibodies. Currently approved MABs have been shown to be effective against current variants including Delta. https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/summary- recommendations/ https://science.sciencemag.org/content/371/6531/850 Who is Eligible to Receive Monoclonal Antibodies? Monoclonal antibodies have Federal Drug Administration (FDA) emergency use approval for the treatment of mild to moderate COVID-19 positive patients within the first 10 days of diagnosis
    [Show full text]
  • COVID-19 (Updated 06/29/2021)
    COVID-19 (Updated 06/29/2021) TABLE OF CONTENTS What’s New: ............................................................................................................................................ 2 Coding for COVID-19 ............................................................................................................................... 3 Coding for Confirmed COVID-19 .............................................................................................................. 4 Coding for Exposure to COVID-19 ............................................................................................................ 5 Coding for Screening of COVID-19 ........................................................................................................... 5 Coding for Preprocedural or Admission Protocol COVID-19 ..................................................................... 6 Coding for Signs and Symptoms without a Definitive Diagnosis of COVID-19............................................ 7 COVID-19 Specimen Collection ................................................................................................................ 7 Inpatient Treatment for COVID-19 ........................................................................................................... 8 No Positive COVID-19 test result available ............................................................................................... 8 PHE Status Renewed 4/21/2021 -- Another 90 Days (July 20, 2021) ........................................................
    [Show full text]
  • Emerging Treatment Update: Suspected COVID-19 P.1
    Indian Health Service National Pharmacy and Therapeutics Committee COVID-19 Emerging Treatments Update June 29, 2021 Pause in Distribution and Utilization of Bamlanivimab/Etesevimab On June 25, 2021, the HHS Assistant Secretary for Preparedness and Response (ASPR) announced an immediate pause involving distribution of bamlanivimab and etesevimab together and etesevimab alone (to pair with an existing supply of bamlanivimab) on a national basis until further notice. In addition, the FDA recommends that health care providers nationwide use alternative authorized monoclonal antibody therapies (REGEN-COV and Sotrovimab), as described below, and to avoid use of bamlanivimab and etesevimab administered together for the management of COVID-19 at this time.1 The Centers for Disease Control and Prevention has identified that the combined frequencies of the SARS-CoV-2 P.1/Gamma variant (first identified in Brazil) and the B.1.351/Beta variant (first identified in South Africa) throughout the United States now exceed 11% and are trending upward (https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-proportions.html).2 Results from in-vitro assays used to assess the susceptibility of viral variants to particular monoclonal antibodies suggest that bamlanivimab and etesevimab administered together are not active against either the P.1 or B.1.351 variants. Lack of bamlanivimab/etesevimab activity against the COVID-19 P.1 variant has been suspected and reported earlier.3 REGEN-COV and sotrovimab are alternative monoclonal antibody therapies that are currently authorized for the same use as bamlanivimab and etesevimab administered together. Based on similar in-vitro assay data currently available, REGEN-COV and sotrovimab are likely to retain activity against the P.1 or B.1.351 variants.
    [Show full text]
  • May 2021 Monitoring International Trends
    Monitoring International Trends May 2021 The NBA monitors international developments that may influence the management of blood and blood products in Australia. Our focus is on: Potential new product developments and applications; Global regulatory and blood practice trends; Events that may have an impact on global supply, demand and pricing, such as changes in company structure, capacity, organisation and ownership; and Other emerging risks that could put financial or other pressures on the Australian sector. Highlights include: Research and development in the health sector, and clinical trials, continue to have a strong focus on pandemic related matters, although other issues are receiving more attention than a year ago. Professional societies are holding virtual conferences and annual meetings. Some developments in treating blood disorders (hereditary angioedema, paroxysmal nocturnal haemoglobinuria, and haemophilia) are described on page 3. Hereditary angioedema patients in the United States, the European Union and Japan now have the option of oral prophylaxis rather than injection or infusion. Researchers reinforced the view that the use of tranexamic acid in hip and knee arthroplasties could reduce blood transfusions (page 3). Others found that intravenous immunoglobulin did not relieve the pain of idiopathic small fibre neuropathy (page 4). Some scientists are estimating the life of antibodies in people who have had a COVID-19 infection (page 4), others are trialling the efficacy of monoclonal antibodies in treating the disease (pages 4 and 5), and there is interest in what is termed “long COVID” (page 4). With a number of COVID-19 vaccines in large-scale use, discussion continues about their effectiveness against a variety of variants, their possible side effects, whether they should be used sequentially in the same patients, how much they permit break-through infection, whether they prevent disease transmission to others, how long the immunity they produce will last and whether boosters will be required (pages 6 to 9).
    [Show full text]
  • Assessment Report
    20 May 2021 EMA/304600/2021 Committee for Medicinal Products for Human Use (CHMP) Assessment report Procedure under Article 5(3) of Regulation (EC) No 726/2004 GlaxoSmithKline use of sotrovimab (VIR-7831/GSK4182136) for the treatment of COVID-19 INN/active substance: sotrovimab Procedure number: EMEA/H/A-5(3)/1508 Note: Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. Table of contents Table of contents ......................................................................................... 2 1. Information on the procedure ................................................................. 3 2. Scientific discussion ................................................................................ 3 2.1. Introduction ...................................................................................................... 3 2.2. Clinical aspects .................................................................................................. 4 2.2.1. Clinical pharmacology ...................................................................................... 6 2.2.2. Data on efficacy ...........................................................................................
    [Show full text]
  • Policy Brief 002 Update 04.2021.Pdf
    .................................................................................................................................................................. 3 1 Background: policy question and methods ................................................................................................. 7 1.1 Policy Question ............................................................................................................................................. 7 1.2 Methodology ................................................................................................................................................. 7 1.3 Selection of Products for “Vignettes” ........................................................................................................ 10 2 Results: Vaccines ......................................................................................................................................... 13 2.1 Moderna Therapeutics—US National Institute of Allergy ..................................................................... 22 2.2 University of Oxford/ Astra Zeneca .......................................................................................................... 23 2.3 BioNTech/Fosun Pharma/Pfizer .............................................................................................................. 25 2.4 Janssen Pharmaceutical/ Johnson & Johnson .......................................................................................... 27 2.5 Novavax ......................................................................................................................................................
    [Show full text]
  • EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology's
    CORRECTION -- EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology’s Sotrovimab For the Early Treatment of COVID-19 May 21, 2021 – Opinion based on the EMA’s Committee for Human Medicinal Products (CHMP) review of available data on sotrovimab (previously VIR-7831) for the early treatment of COVID-19 – – EU member states can use the CHMP positive scientific opinion when making national decisions about the early use of sotrovimab prior to EMA marketing authorization – – Discussions with global regulators regarding authorizations in additional countries continue to advance – LONDON and SAN FRANCISCO, May 21, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Vir Biotechnology, Inc. please note that the third sub headline of the release has been updated. The corrected release follows: GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced that the European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has issued a positive scientific opinion following the referral of sotrovimab to the CHMP under Article 5(3) of Regulation 726/2004. The opinion relates to the use of sotrovimab for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with COVID-19 who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19. The CHMP opinion under Article 5(3) can now be considered by the national authorities in EU member states when taking evidence-based decisions on the early use of the medicine prior to marketing authorization. Christopher Corsico, senior vice president, development, GSK, said: “As the COVID-19 pandemic continues and the virus generates new variants of concern, including those that recently emerged in India, the need for therapies that can slow the progression of disease in patients who are at high risk for developing severe complications remains a top priority.
    [Show full text]